Insider-Favored Growth Stocks To Watch In January 2025

As global markets continue to react positively to recent political developments and the potential for a trade deal between the U.S. and China, major indices like the S&P 500 have reached record highs, buoyed by enthusiasm for AI investments. In this context of optimism and growth, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company's operations.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Kirloskar Pneumatic (BSE:505283)	30.3%	26.3%
Archean Chemical Industries (NSEI:ACI)	22.9%	41.2%
Laopu Gold (SEHK:6181)	36.4%	36.6%
Waystream Holding (OM:WAYS)	11.3%	113.3%
Medley (TSE:4480)	34.1%	27.3%
Brightstar Resources (ASX:BTR)	16.2%	84.1%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	135%
Fulin Precision (SZSE:300432)	13.6%	71%
HANA Micron (KOSDAQ:A067310)	18.2%	119.4%
Elliptic Laboratories (OB:ELABS)	26.8%	121.1%

Click here to see the full list of 1470 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

MicroTech Medical (Hangzhou) (SEHK:2235)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MicroTech Medical (Hangzhou) Co., Ltd. focuses on the research, development, manufacture, and sale of medical devices for diabetes management both in China and internationally, with a market cap of HK$2.38 billion.

Operations: The company's revenue segment comprises CN¥293.23 million from its operations in developing, manufacturing, and selling medical devices for diabetes care.

Insider Ownership: 25.9%

MicroTech Medical (Hangzhou) is poised for significant growth, with revenue projected to increase by 35.6% annually, outpacing the Hong Kong market's 7.6%. The company is expected to achieve profitability within three years, with earnings forecasted to grow at a substantial rate of 99.57% per year. Despite limited recent insider trading data, high insider ownership aligns management interests with shareholders, potentially enhancing long-term value creation as the company expands its market presence.

• Dive into the specifics of MicroTech Medical (Hangzhou) here with our thorough growth forecast report.
• The valuation report we've compiled suggests that MicroTech Medical (Hangzhou)'s current price could be inflated.

Sino Medical Sciences Technology (SHSE:688108)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sino Medical Sciences Technology Inc. is a medical device company focused on the research, development, production, and distribution of interventional devices in China with a market cap of CN¥4.06 billion.

Operations: The company generates revenue primarily from its medical products segment, which amounted to CN¥417.13 million.

Insider Ownership: 25.8%

Sino Medical Sciences Technology is set for robust growth, with revenue projected to rise by 43.4% annually, surpassing the Chinese market's 13.4%. The company is expected to achieve profitability within three years, with earnings forecasted to grow at an impressive rate of 119.49% per year. Recent financial results show a significant reduction in net loss from CNY 41.75 million to CNY 6.74 million over nine months, indicating improved operational efficiency and potential future profitability despite limited insider trading data recently available.

• Delve into the full analysis future growth report here for a deeper understanding of Sino Medical Sciences Technology.
• Our valuation report unveils the possibility Sino Medical Sciences Technology's shares may be trading at a premium.

Shenzhen Senior Technology Material (SZSE:300568)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shenzhen Senior Technology Material Co., Ltd. operates in the production and sale of high-performance separator materials for lithium-ion batteries, with a market cap of CN¥13.18 billion.

Operations: The company's revenue primarily comes from its Lithium-Ion Battery Separator New Energy Materials segment, which generated CN¥3.38 billion.

Insider Ownership: 12.8%

Shenzhen Senior Technology Material is poised for substantial growth, with earnings expected to increase by 39.87% annually, outpacing the Chinese market's 25.1%. Despite this promising outlook, recent financial results reveal a decline in net income to CNY 349.37 million from CNY 667.57 million year-on-year, and profit margins have decreased significantly. The company's revenue growth forecast of 25.7% per year remains strong despite no notable insider trading activity recently reported.

• Get an in-depth perspective on Shenzhen Senior Technology Material's performance by reading our analyst estimates report here.
• Insights from our recent valuation report point to the potential undervaluation of Shenzhen Senior Technology Material shares in the market.

Key Takeaways

• Explore the 1470 names from our Fast Growing Companies With High Insider Ownership screener here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com